Virax Biolabs signs exclusive immune profiling supply deal with Fosun Diagnostics

Virax Biolabs will provide ImmuneSelect products · Medical Device Network

By Salong Debbarma Mon, July 13, 2026 at 2:48 AM PDT | 2 min read

• VRAX: -35.85%

Virax Biolabs Group subsidiary Virax Biolabs (UK) has signed an exclusive commercial supply agreement with Fosun Diagnostics for its research-use-only ImmuneSelect immune profiling product line.

Fosun is the key entity of the diagnostics business under Fosun Medtech, a division of Fosun Pharma.

Geographic Scope

The agreement covers six Southeast Asian countries:

• Indonesia
• Malaysia
• Philippines
• Singapore
• Thailand
• Vietnam

Key Terms and Commercial Structure

• The agreement allows for immediate product supply in response to purchase orders.
• It aims to support near-term revenue prospects and regional business growth.
• Virax Biolabs will provide ImmuneSelect products, including ELISpot assay plates used to measure cellular immune responses, to Fosun Diagnostics based on structured, volume-based pricing tiers.
• The exclusivity of the agreement is tied to minimum purchase and performance criteria.

Initial Focus and Expansion Plans

The collaboration initially focuses on tuberculosis-related research applications in Thailand, where Fosun has identified immediate customer interest and begun evaluation activities through Fosun Pharma's regional network. This rollout could later extend across other countries in the region.

The deal provides a framework for phased expansion that may include:

• Additional products
• Larger-scale supply
• Potential original equipment manufacturer (OEM) or private-label arrangements

Executive Commentary

James Foster, Chairman and CEO of Virax Biolabs, said:

"This agreement represents a major step forward in the commercial rollout of our ImmuneSelect platform across Southeast Asia. It establishes a structured multi-country framework with one of Asia's leading diagnostics groups, enabling immediate commercial activity and a clear pathway for scalable regional expansion."

Leon Zhang, Head of International Commercial Business for Fosun MedTech China Domestic Business, said:

"We are pleased to collaborate with Virax Biolabs as we evaluate ELISpot-based research applications across Southeast Asia. Virax's ImmuneSelect ELISpot platform provides a strong option for our evaluation activities, and we look forward to assessing its performance across multiple regional markets."

Note on Product Differentiation

ImmuneSelect is distinct from ViraxImmune, Virax's separate diagnostic platform that remains under development.

"Virax Biolabs enters immune profiling product supply deal with Fosun" was originally created and published by Medical Device Network, a GlobalData owned brand.